Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02668653
Title Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo Inc.

acute myeloid leukemia


Cytarabine + Daunorubicin + Idarubicin

Cytarabine + Daunorubicin + Idarubicin + Quizartinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Additional content available in CKB BOOST